Brokers Issue Forecasts for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at William Blair issued their Q2 2025 earnings estimates for shares of Vertex Pharmaceuticals in a note issued to investors on Tuesday, May 6th. William Blair analyst M. Minter anticipates that the pharmaceutical company will post earnings per share of $3.95 for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $4.16 EPS and Q4 2025 earnings at $4.54 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $4.76 earnings per share.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. upped their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a research report on Tuesday. BMO Capital Markets set a $545.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target on the stock. in a report on Thursday, January 30th. Royal Bank of Canada upped their price objective on Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a “sector perform” rating in a research note on Tuesday. Finally, Leerink Partnrs lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Thirteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $515.04.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $425.30 on Thursday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $109.34 billion, a P/E ratio of -193.32, a PEG ratio of 2.11 and a beta of 0.51. The business has a 50 day simple moving average of $488.74 and a 200-day simple moving average of $465.90. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

Insider Buying and Selling

In other news, EVP David Altshuler sold 3,231 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 in the last three months. Corporate insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Capital World Investors grew its holdings in shares of Vertex Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after buying an additional 1,514,993 shares in the last quarter. Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company’s stock worth $11,388,985,000 after acquiring an additional 232,873 shares during the last quarter. Capital Research Global Investors grew its stake in Vertex Pharmaceuticals by 15.8% in the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after acquiring an additional 1,426,746 shares during the period. Wellington Management Group LLP grew its stake in Vertex Pharmaceuticals by 23.3% in the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock worth $2,382,407,000 after acquiring an additional 1,117,214 shares during the period. Finally, Jennison Associates LLC raised its holdings in Vertex Pharmaceuticals by 17.2% in the 1st quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock valued at $2,454,373,000 after acquiring an additional 744,680 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.